Cancer despite immunosurveillance: immunoselection and immunosubversion
The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.
Abstract
Numerous innate and adaptive immune effector cells and molecules participate in the recognition and destruction of cancer cells, a process that is known as cancer immunosurveillance. But cancer cells avoid such immunosurveillance through the outgrowth of poorly immunogenic tumour-cell variants (immunoselection) and through subversion of the immune system (immunosubversion). At the early stages of carcinogenesis, cell-intrinsic barriers to tumour development seem to be associated with stimulation of an active antitumour immune response, whereas overt tumour development seems to correlate with changes in the immunogenic properties of tumour cells. The permanent success of treatments for cancer might depend on using immunogenic chemotherapy to re-establish antitumour immune responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cancers must escape from immunosurveillance to advance to a clinically detectable state, meaning that they either are passively selected to ''hide'' from immune recognition (immunoselection) or actively suppress immune effectors (immunosubversion).249”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [249]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992 · cited 1×
“By contrast, it is thought that TGFβ can also have immunostimulatory effects (in particular, on specific T H -cell subset”
BackgroundCuriel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
The Pathophysiology of Mitochondrial Cell Death
Green, D. R., & Kroemer, G. (2004) · Science · doi:10.1126/science.1099320 · Cited by 3,418
Sakaguchi, S. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141122 · Cited by 3,306
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 1×
“More importantly, tryptophan degradation by indoleamine 2,3-dioxygenase ( IDO ), which is constitutively expressed by human tumours (particularly by prostate, colon and pancreatic carcinomas, but also by interdigitating DCs), promotes resistance to immune-mediated rejection of the tumour cell”
BackgroundImmunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions
Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775 · cited 1×
“For example, some tumours (or tumour-associated myeloid cells) overproduce nitric oxide and have increased arginase-1 activity, both of which can inhibit T-cell functio”
BackgroundReits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512 · cited 1×
“Indeed, activation of caspases might be required to elicit immunogenic tumour-cell death in an in vivo model of anthracycline-mediated antitumour chemotherap”
BackgroundSelf-citationSenescence in premalignant tumours
Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A. J., Barradas, M., Benguría, A., Zaballos, A., Flores, J. M., Barbacid, M., et al. (2005) · Nature · doi:10.1038/436642a · Cited by 1,482 · cited 1×
“Indeed, one of the markers of senescent tumour cells, decoy receptor 2 (also known as TNFRSF10D), suppresses TRAIL-induced apoptosi”
BackgroundRoles of the NKG2D immunoreceptor and its ligands
Raulet, D. H. (2003) · Nature Reviews Immunology · doi:10.1038/nri1199 · Cited by 1,348
Lowe, S. W., Cepero, E., & Evan, G. (2004) · Nature · doi:10.1038/nature03098 · Cited by 1,309
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor
Gasser, S., Orsulic, S., Brown, E. J., & Raulet, D. H. (2005) · Nature · doi:10.1038/nature03884 · Cited by 1,308
Lysosomes and autophagy in cell death control
Kroemer, G., & Jäättelä, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1738 · Cited by 1,285
Ghiringhelli, F., Menard, C., Puig, P. E., Ladoire, S., Roux, S., Martin, F., Solary, E., Le Cesne, A., Zitvogel, L., & Chauffert, B. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0225-8 · Cited by 1,241
Oncogene-induced senescence as an initial barrier in lymphoma development
Braig, M., Lee, S., Loddenkemper, C., Rudolph, C., Peters, A. H. F. M., Schlegelberger, B., Stein, H., Dörken, B., Jenuwein, T., & Schmitt, C. A. (2005) · Nature · doi:10.1038/nature03841 · Cited by 1,220
Imai, K., Matsuyama, S., Miyake, S., Suga, K., & Nakachi, K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03231-1 · Cited by 1,190
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
Wang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., Zhang, S., Bhattacharya, R., Gabrilovich, D., Heller, R., Coppola, D., et al. (2004) · Nature Medicine · doi:10.1038/nm976 · Cited by 1,155
Inactivation of the apoptosis effector Apaf-1 in malignant melanoma
Soengas, M. S., Capodieci, P., Polsky, D., Mora, J., Esteller, M., Opitz-Araya, X., McCombie, R., Herman, J. G., Gerald, W. L., Lazebnik, Y. A., et al. (2001) · Nature · doi:10.1038/35051606 · Cited by 966
Ghiringhelli, F., Ménard, C., Terme, M., Flament, C., Taieb, J., Chaput, N., Puig, P. E., Novault, S., Escudier, B., Vivier, E., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051511 · Cited by 949
Terness, P., Bauer, T. M., Röse, L., Dufter, C., Watzlik, A., Simon, H., & Opelz, G. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020052 · Cited by 937
Smyth, M. J., Dunn, G. P., & Schreiber, R. D. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90001-7 · Cited by 870
Takaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., et al. (2003) · Nature · doi:10.1038/nature01850 · Cited by 847 · cited 1×
“, can upregulate the p53-mediated response of tumour cell”
BackgroundTransforming growth factor-β in T-cell biology
Gorelik, L., & Flavell, R. A. (2002) · Nature Reviews Immunology · doi:10.1038/nri704 · Cited by 792 · cited 1×
“Among other functions, TGFβ reduces the amount of antigen presentation by DCs, inhibits the activity of IFNγ, reduces the proliferation of T cells, suppresses the cytotoxic activity of NK cells and stimulates the proliferation of T Reg cell”
BackgroundGhiringhelli, F., Puig, P. E., Roux, S., Parcellier, A., Schmitt, E., Solary, E., Kroemer, G., Martin, F., Chauffert, B., & Zitvogel, L. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050463 · Cited by 776
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma
Kryczek, I., Zou, L., Rodriguez, P., Zhu, G., Wei, S., Mottram, P., Brumlik, M., Cheng, P., Curiel, T., Myers, L., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20050930 · Cited by 748 · cited 1×
“IL-6 and IL-10 have also been found to stimulate a B7-H4-expressing T-cell-suppressive macrophage population in patients with ovarian carcinom”
BackgroundCaspase-independent cell death
Kroemer, G., & Martin, S. J. (2005) · Nature Medicine · doi:10.1038/nm1263 · Cited by 716
Gastpar, R., Gehrmann, M., Bausero, M. A., Asea, A., Gross, C., Schroeder, J. A., & Multhoff, G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3804 · Cited by 695
Viguier, M., Lemaître, F., Verola, O., Cho, M.-S., Gorochov, G., Dubertret, L., Bachelez, H., Kourilsky, P., & Ferradini, L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.1444 · Cited by 686
A critical function for type I interferons in cancer immunoediting
Dunn, G. P., Bruce, A. T., Sheehan, K. C. F., Shankaran, V., Uppaluri, R., Bui, J. D., Diamond, M. S., Koebel, C. M., Arthur, C., White, J. M., et al. (2005) · Nature Immunology · doi:10.1038/ni1213 · Cited by 605
Autoantibody Signatures in Prostate Cancer
Wang, X., Yu, J., Sreekumar, A., Varambally, S., Shen, R., Giacherio, D., Mehra, R., Montie, J. E., Pienta, K. J., Sanda, M. G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051931 · Cited by 582
Guiducci, C., Vicari, A. P., Sangaletti, S., Trinchieri, G., & Colombo, M. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4262 · Cited by 549
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression
Ohm, J. E., Gabrilovich, D. I., Sempowski, G. D., Kisseleva, E., Parman, K. S., Nadaf, S., & Carbone, D. P. (2003) · Blood · doi:10.1182/blood-2002-07-1956 · Cited by 538
Death receptors in chemotherapy and cancer
Debatin, K.-M., & Krammer, P. H. (2004) · Oncogene · doi:10.1038/sj.onc.1207558 · Cited by 505
Takeda, K., Smyth, M. J., Cretney, E., Hayakawa, Y., Kayagaki, N., Yagita, H., & Okumura, K. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011171 · Cited by 465
Stolina, M., Sharma, S., Lin, Y., Dohadwala, M., Gardner, B., Luo, J., Zhu, L., Kronenberg, M., Miller, P. W., Portanova, J., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.1.361 · Cited by 465
Oppenheim, D. E., Roberts, S. J., Clarke, S. L., Filler, R., Lewis, J. M., Tigelaar, R. E., Girardi, M., & Hayday, A. C. (2005) · Nature Immunology · doi:10.1038/ni1239 · Cited by 454
Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance
Willimsky, G., & Blankenstein, T. (2005) · Nature · doi:10.1038/nature03954 · Cited by 445
COX-2: A Molecular Target for Colorectal Cancer Prevention
Brown, J. R., & DuBois, R. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.051 · Cited by 444
Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN- gamma .
Billiau, A., Heremans, H., Vandekerckhove, F., Dijkmans, R., Sobis, H., Meulepas, E., & Carton, H. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.5.1506 · Cited by 435
Post-Transplant Malignancy: The Role Of Immunosuppression
Penn, I. (2000) · Drug Safety · doi:10.2165/00002018-200023020-00002 · Cited by 414
A novel dendritic cell subset involved in tumor immunosurveillance
Taieb, J., Chaput, N., Ménard, C., Apetoh, L., Ullrich, E., Bonmort, M., Péquignot, M., Casares, N., Terme, M., Flament, C., et al. (2006) · Nature Medicine · doi:10.1038/nm1356 · Cited by 405
Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis
Dohi, T., Beltrami, E., Wall, N. R., Plescia, J., & Altieri, D. C. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422222 · Cited by 405
Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers
Bronte, V., Kasic, T., Gri, G., Gallana, K., Borsellino, G., Marigo, I., Battistini, L., Iafrate, M., Prayer-Galetti, T., Pagano, F., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042028 · Cited by 396
Plasmacytoid Dendritic Cells Induce CD8+ Regulatory T Cells In Human Ovarian Carcinoma
Wei, S., Kryczek, I., Zou, L., Daniel, B., Cheng, P., Mottram, P., Curiel, T., Lange, A., & Zou, W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4043 · Cited by 379
Spinning molecular immunology into successful immunotherapy
Pardoll, D. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri774 · Cited by 360
Armeanu, S., Bitzer, M., Lauer, U. M., Venturelli, S., Pathil, A., Krusch, M., Kaiser, S., Jobst, J., Smirnow, I., Wagner, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4252 · Cited by 358
Medema, J. P., de Jong, J., Peltenburg, L. T. C., Verdegaal, E. M. E., Gorter, A., Bres, S. A., Franken, K. L. M. C., Hahne, M., Albar, J. P., Melief, C. J. M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201398198 · Cited by 356
NKG2D function protects the host from tumor initiation
Smyth, M. J., Swann, J., Cretney, E., Zerafa, N., Yokoyama, W. M., & Hayakawa, Y. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050994 · Cited by 342
Bennett, M. W., O’Connell, J., O’Sullivan, G. C., Brady, C., Roche, D., Collins, J. K., & Shanahan, F. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.11.5669 · Cited by 326
Borg, C., Terme, M., Taïeb, J., Ménard, C., Flament, C., Robert, C., Maruyama, K., Wakasugi, H., Angevin, E., Thielemans, K., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21102 · Cited by 302 · cited 1×
“Similarly, imatinib mesylate can stimulate the activity of NK cells, correlating with a favourable clinical outcome for patients with gastrointestinal stromal tumour”
BackgroundDendritic Cell Subsets Differentially Regulate Angiogenesis in Human Ovarian Cancer
Curiel, T. J., Cheng, P., Mottram, P., Alvarez, X., Moons, L., Evdemon-Hogan, M., Wei, S., Zou, L., Kryczek, I., Hoyle, G., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1272 · Cited by 297
Binder, R. J., & Srivastava, P. K. (2005) · Nature Immunology · doi:10.1038/ni1201 · Cited by 295
Targeting Apoptosis Pathways in Cancer Therapy
Fulda, S., & Debatin, K.-M. (2004) · Current Cancer Drug Targets · doi:10.2174/1568009043332763 · Cited by 290
Immunoregulatory T cells in tumor immunity
Terabe, M., & Berzofsky, J. A. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.01.010 · Cited by 264
Andersen, M. H., Pedersen, L. Ø., Becker, J. C., & Straten, P. T. (2001) · PubMed · Cited by 258
Soluble MICA in malignant diseases
Holdenrieder, S., Stieber, P., Peterfi, A., Nagel, D., Steinle, A., & Salih, H. R. (2006) · International Journal of Cancer · doi:10.1002/ijc.21382 · Cited by 240
Carrington, M., Wang, S., Martin, M. P., Gao, X., Schiffman, M., Cheng, J., Herrero, R., Rodriguez, A. C., Kurman, R., Mortel, R., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042158 · Cited by 231
Coudert, J. D., Zimmer, J., Tomasello, E., Cebecauer, M., Colonna, M., Vivier, E., & Held, W. (2005) · Blood · doi:10.1182/blood-2005-03-0918 · Cited by 226
Tumor–Host Immune Interactions and Dendritic Cell Dysfunction
(2004) · Advances in Cancer Research · doi:10.1016/s0065-230x(04)92002-7 · Cited by 223
Dhodapkar, M. V., Krasovsky, J., Osman, K., & Geller, M. D. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20031030 · Cited by 217
Boles, K. S., Barchet, W., Diacovo, T., Cella, M., & Colonna, M. (2005) · Blood · doi:10.1182/blood-2005-02-0817 · Cited by 208
A proportion of patients with lymphoma may harbor mutations of the perforin gene
Clementi, R. (2005) · Blood · doi:10.1182/blood-2004-04-1477 · Cited by 188
Immune Enhancement of Skin Carcinogenesis by CD4+ T Cells
Daniel, D., Meyer-Morse, N., Bergsland, E. K., Dehne, K., Coussens, L. M., & Hanahan, D. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021047 · Cited by 180
Stefanidakis, M., & Koivunen, E. (2006) · Blood · doi:10.1182/blood-2006-02-005363 · Cited by 175
Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer
Smyth, M. J., Wallace, M. E., Nutt, S. L., Yagita, H., Godfrey, D. I., & Hayakawa, Y. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042280 · Cited by 172
Hayashi, T., Imai, K., Morishita, Y., Hayashi, I., Kusunoki, Y., & Nakachi, K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2776 · Cited by 172
Increased incidence of melanoma in renal transplantation recipients
Hollenbeak, C. S., Todd, M. M., Billingsley, E. M., Harper, G., Dyer, A., & Lengerich, E. J. (2005) · Cancer · doi:10.1002/cncr.21404 · Cited by 169
Carbone, D. P., Ciernik, I. F., Kelley, M. J., Smith, M. C., Nadaf, S., Kavanaugh, D., Maher, V. E., Stipanov, M., Contois, D., Johnson, B. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.158 · Cited by 169
Dual Role of Transforming Growth Factor β in Mammary Tumorigenesis and Metastatic Progression
Muraoka-Cook, R. S., Dumont, N., & Arteaga, C. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.937s.11.2 · Cited by 168
Watson, N. F. S., Spendlove, I., Madjd, Z., McGilvray, R., Green, A. R., Ellis, I. O., Scholefield, J. H., & Durrant, L. G. (2006) · International Journal of Cancer · doi:10.1002/ijc.21510 · Cited by 166
Stassi, G., Todaro, M., Zerilli, M., Ricci‐Vitiani, L., Liberto, D. D., Patti, M., Florena, A., Gaudio, F. D., Gesù, G. D., & Maria, R. D. (2003) · PubMed · Cited by 164
Conticello, C., Pedini, F., Zeuner, A., Patti, M., Zerilli, M., Stassi, G., Messina, A., Peschle, C., & De Maria, R. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.9.5467 · Cited by 162
Schmitz-Winnenthal, F. H., Volk, C., Z'graggen, K., Galindo, L., Nummer, D., Ziouta, Y., Bucur, M., Weitz, J., Schirrmacher, V., Büchler, M. W., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1098 · Cited by 161
Beckhove, P., Feuerer, M., Dolenc, M., Schütz, F., Choi, C., Sommerfeldt, N., Schwendemann, J., Ehlert, K., Altevogt, P., Bastert, G., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci20278 · Cited by 157
Immune Response Against Dying Tumor Cells
Zitvogel, L., Casares, N., Péquignot, M. O., Chaput, N., Albert, M. L., & Kroemer, G. (2004) · Advances in immunology · doi:10.1016/s0065-2776(04)84004-5 · Cited by 148
Zhang, Q., Yang, X., Pins, M., Javonovic, B., Kuzel, T., Kim, S.-J., Parijs, L. V., Greenberg, N. M., Liu, V., Guo, Y., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3169 · Cited by 146
Message in a bottle: Role of the 70‐kDa heat shock protein family in anti‐tumor immunity
Calderwood, S. K., Thériault, J. R., & Gong, J. (2005) · European Journal of Immunology · doi:10.1002/eji.200535002 · Cited by 137
Atkins, D., Breuckmann, A., Schmahl, G. E., Binner, P., Ferrone, S., Krummenauer, F., Störkel, S., & Seliger, B. (2004) · International Journal of Cancer · doi:10.1002/ijc.11681 · Cited by 135
Ren, J., Bharti, A. K., Raina, D. B., Chen, W., Ahmad, R., & Kufe, D. W. (2005) · Oncogene · doi:10.1038/sj.onc.1209012 · Cited by 134
Monti, P., Leone, B. E., Zerbi, A., Balzano, G., Cainarca, S., Sordi, V., Pontillo, M., Mercalli, A., Carlo, V. D., Allavena, P., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.12.7341 · Cited by 132
Sun, T., Zhou, Y., Li, H., Han, X., Shi, Y., Wang, L., Miao, X., Tan, W., Zhao, D., Zhang, X., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050707 · Cited by 124
XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis
Tamm, I., Richter, S., Scholz, F. R., Schmelz, K., Oltersdorf, D., Karawajew, L., Schoch, C., Haferlach, T., Ludwig, W.-D., & Wuchter, C. (2004) · The Hematology Journal · doi:10.1038/sj.thj.6200549 · Cited by 119
Suzuki, H., Graziano, D. F., McKolanis, J., & Finn, O. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0538 · Cited by 113
The role of dendritic cell precursors in tumour vasculogenesis
Coukos, G., Benencia, F., Buckanovich, R. J., & Conejo-Garcia, J. R. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602476 · Cited by 112
Carlos, C. A., Dong, H. F., Howard, O. M. Z., Oppenheim, J. J., Hanisch, F.-G., & Finn, O. J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.3.1628 · Cited by 102
Zhou, G., Lu, Z., McCadden, J. D., Levitsky, H. I., & Marson, A. L. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20041240 · Cited by 102
Recovery of CD8+ T-Cell Function During Systemic Chemotherapy in Advanced Ovarian Cancer
Coleman, S. L., Clayton, A., Mason, M. D., Jasani, B., Adams, M., & Tabi, Z. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3792 · Cited by 99
Okada, K., Komuta, K., Hashimoto, S., Matsuzaki, S., Kanematsu, T., & Koji, T. (2000) · PubMed · Cited by 99
Tumor counterattack: Fact or fiction?
Igney, F. H., & Krammer, P. H. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-005-0680-7 · Cited by 98 · cited 1×
“The expression of CD95L at the surface of tumour cells might contribute to the deletion of CD95-expressing activated T cells that invade the tumou”
BackgroundHaplotype Loss of HLA Class I Antigen as an Escape Mechanism from Immune Attack in Lung Cancer
So, T., Takenoyama, M., Mizukami, M., Ichiki, Y., Sugaya, M., Hanagiri, T., Sugio, K., & Yasumoto, K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3787 · Cited by 97
Berd, D., & Mastrangelo, M. J. (1987) · PubMed · Cited by 96
p53 autoantibodies predict subsequent development of cancer
Li, Y., Karjalainen, A., Koskinen, H., Hemminki, K., Vainio, H., Shnaidman, M., Ying, Z., Pukkala, ., & Brandt‐Rauf, P. W. (2004) · International Journal of Cancer · doi:10.1002/ijc.20715 · Cited by 92
Della Porta, M., Danova, M., Rigolin, G. M., Brugnatelli, S., Rovati, B., Tronconi, C., Fraulini, C., Russo Rossi, A., Riccardi, A., & Castoldi, G. (2005) · Oncology · doi:10.1159/000086784 · Cited by 91
CD95L/FasL and TRAIL in Tumour Surveillance and Cancer Therapy
Wajant, H. (2006) · Cancer treatment and research · doi:10.1007/0-387-26283-0_7 · Cited by 90
Tanimoto, T., Tsuda, H., Imazeki, N., Ohno, Y., Imoto, I., Inazawa, J., & Matsubara, O. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.11.049 · Cited by 70
Immunological ignorance of solid tumors
Ochsenbein, A. F. (2005) · Springer Seminars in Immunopathology · doi:10.1007/s00281-004-0192-0 · Cited by 70
Scott, C. L., Schuler, M., Marsden, V. S., Egle, A., Pellegrini, M., Nesic, D., Gerondakis, S., Nutt, S. L., Green, D. R., & Strasser, A. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200310041 · Cited by 69
Asanuma, K., Tsuji, N., Endoh, T., Yagihashi, A., & Watanabe, N. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.6.3922 · Cited by 68
Nabarro, S., Himoudi, N., Papanastasiou, A., Gilmour, K. C., Gibson, S., Sebire, N. J., Thrasher, A. J., Blundell, M. P., Hubank, M. J. F., Canderan, G., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050730 · Cited by 62
Perspectives on cancer immuno‐epidemiology
Nakachi, K., Hayashi, T., Imai, K., & Kusunoki, Y. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03178.x · Cited by 58
Simultaneous Cellular and Humoral Immune Response against Mutated p53 in a Patient with Lung Cancer
Ichiki, Y., Takenoyama, M., Mizukami, M., So, T., Sugaya, M., Yasuda, M., So, T., Hanagiri, T., Sugio, K., & Yasumoto, K. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.8.4844 · Cited by 55
Bonnotte, B., Crittenden, M. R., Larmonier, N., Gough, M. J., & Vile, R. G. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.8.4929 · Cited by 55
DNA-based vaccines activate innate and adaptive antitumor immunity by engaging the NKG2D receptor
Zhou, H., Luo, Y., Lo, J., Kaplan, C. D., Mizutani, M., Mizutani, N., Lee, J.-D., Primus, F. J., Becker, J. C., Xiang, R., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502208102 · Cited by 55
Autoantigens act as tissue-specific chemoattractants
Oppenheim, J. J., Dong, H. F., Plotz, P., Caspi, R. R., Dykstra, M., Pierce, S., Martin, R., Carlos, C., Finn, O., Koul, O., et al. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.1004623 · Cited by 49
Impaired monocyte function in cancer patients: restoration with a cyclooxygenase‐2 inhibitor
Lang, S., Lauffer, L. M., Clausen, C., Löhr, I., Schmitt, B., Hölzel, D., Wollenberg, B., Gires, O., Kastenbauer, E. R., & Zeidler, R. (2002) · The FASEB Journal · doi:10.1096/fj.02-0417fje · Cited by 48
Spontaneous Immunity against Bcl-xL in Cancer Patients
Andersen, M. H., Hadrup, S. R., Kvistborg, P., Becker, J. C., & Straten, P. T. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.4.2709 · Cited by 42
Ravi, R., Fuchs, E. J., Jain, A., Pham, V., Yoshimura, K., Prouser, T., Jalla, S., Zhou, X., Garrett-Mayer, E., Kaufmann, S. H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3377 · Cited by 41
HER‐2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine
Pupa, S. M., Tagliabue, E., Ménard, S., & Anichini, A. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20387 · Cited by 39
Allelic imbalance of APAF-1 locus at 12q23 is related to progression of colorectal carcinoma
Umetani, N., Fujimoto, A., Takeuchi, H., Shinozaki, M., Bilchik, A. J., & Hoon, D. S. �. (2004) · Oncogene · doi:10.1038/sj.onc.1208022 · Cited by 38
Nakamura, E., Megumi, Y., Kobayashi, T., Kamoto, T., Ishitoya, S., Terachi, T., Tachibana, M., Matsushiro, H., Habuchi, T., Kakehi, Y., et al. (2002) · PubMed · Cited by 38
Liu, K., Caldwell, S. A., & Abrams, S. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4269 · Cited by 37
Maecker‐Kolhoff, B., von Bergwelt‐Baildon, M. S., Anderson, K. C., Vonderheide, R. H., Anderson, K. C., Nadler, L. M., & Schultze, J. L. (2005) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2005.02879.x · Cited by 33
Turning On/Off Tumor-Specific CTL Response during Progressive Tumor Growth
Huang, Y., Obholzer, N. D., Fayad, R., & Qiao, L. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.5.3110 · Cited by 29
Epstein-Barr virus nuclear antigen 2 induces interleukin-18 receptor expression in B cells
Pagès, F. (2004) · Blood · doi:10.1182/blood-2004-08-3196 · Cited by 27
Amarnath, S., Dyer, C. E., Ramesh, A., Iwuagwu, O. C., Drew, P. J., & Greenman, J. (2004) · International Journal of Oncology · doi:10.3892/ijo.25.1.211 · Cited by 23
Evaluation of Anticyclin B1 Serum Antibody as a Diagnostic and Prognostic Biomarker for Lung Cancer
Egloff, A. M., Weissfeld, J. L., Land, S. R., & Finn, O. J. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1358.005 · Cited by 22
Faber, P., Fisch, P., Waterhouse, M., Schmitt-Graeff, A. H., Bertz, H., Finke, J., & Spyridonidis, A. (2005) · Blood · doi:10.1182/blood-2005-08-3431 · Cited by 19
Malignant neoplasms in registered cases of primary immunodeficiency syndrome.
Kobayashi, N. (1985) · PubMed · Cited by 19
Chaturvedi, V., Bodner, B. K., Qin, J., & Nickoloff, B. J. (2005) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2005.10.003 · Cited by 14
Versatile Prostate Cancer Treatment with Inducible Caspase and Interleukin-12
Nikitina, E. Y., Desai, S. A., Zhao, X., Song, W., Luo, A. Z., Gangula, R., Slawin, K. M., & Spencer, D. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3119 · Cited by 13
Cited by
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
de Visser, K. E., & Joyce, J. A. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.016 · Cited by 4,059
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
“These authors showed that a recombinant N-terminal fragment of CRT (39-272) is a potent inducer of activation and maturation of B cells and macrophages and can trigger Ig class switching in B cells without T cell help in vitro and in vivo72.”
BackgroundCalreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Self-citation
Metadata
- Authors
- Zitvogel, L., Tesniere, A., & Kroemer, G.
- Affiliations
- Inserm (FR)
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Kroemer, Guido
- Venue
- Nature reviews. Immunology
- Published
- 2006-09-15
- Volume
- 6
- Issue
- 10
- Pages
- 715-727
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W2063192133
- Cited by
- 1,324
- References
- 127
- Citations by year
- 2026: 15 · 2025: 26 · 2024: 62 · 2023: 75 · 2022: 68 · 2021: 63 · 2020: 63 · 2019: 60 · 2018: 66 · 2017: 76 · 2016: 72 · 2015: 81 · 2014: 87 · 2013: 89 · 2012: 82
- FWCI
- 5.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Commission
- Conseil Régional, Île-de-France
- Institut National Du Cancer
- Cancéropôle Ile de France
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tumor surveillance, immunoselection, tumor immunogenicity, antitumor immunity, carcinogenesis, immunogenic chemotherapy
- MeSH terms
- Animals, Humans, Immune Tolerance, Immunologic Surveillance, Neoplasms, T-Lymphocytes, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.